MedTrace Logo

Retrospective Study on the Safety of Nivolumab in Patients With mRCC and Renal Failure

NCT07117409 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 81

Last updated 2025-09-11

No results posted yet for this study

Summary

This is an observational, retrospective, multicenter study aimed to compare the toxicity of Nivolumab in patients with metastatic renal cell carcinoma treated in line II and III stratified into 3 patient groups:

* patients with normal or mildly reduced renal function (GFR\<90 and ≥60 ml/min/1.73 m\^2);
* patients with moderate renal impairment (GFR \<60 e ≥30 ml/min/1.73 m\^2),
* patients with severe renal impairment (GFR \<30 e ≥15 ml/min/1.73 m\^2) Patients must have been treated with Nivolumab, as per clinical practice. All patients who have received at least one drug administration between february 2017 to December 31, 2018 will be enrolled in the study.

Conditions

  • Metastatic Renal Cell Carcinoma

Sponsors & Collaborators

  • Azienda USL Reggio Emilia - IRCCS

    lead OTHER_GOV

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-29
Primary Completion
2022-05-30
Completion
2025-06-30

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07117409 on ClinicalTrials.gov